Authors

Main Content

Top Content

Directory of Authors from the Journal and their last article.

Culley C CarsonView Articles
Curtis L SpraitzarView Articles

Volume 19, Number 2Review Articles

The American Urological Association’s Prostate Cancer Screening Guideline: Which Cancers Will Be Missed in Average-risk Men Aged 40 to 54 Years?

Cancer Screening Update

Thomas E MoodyCurtis L SpraitzarElizabeth EisenhartScott Tully Jr

To determine the impact of the American Urological Association’s (AUA) guideline for early detection of prostate cancer that recommends against routine screening in men aged 40 to 54 years at average risk (eg, white men without a family history of prostate cancer), we undertook a study of 973 men who previously underwent a prostate biopsy at Urology Centers of Alabama (UCA) over the 5-year period from 2010 to 2014. We retrospectively reviewed the results of the prostate biopsies performed by urologists at UCA—and, where applicable, the final surgical pathology results and compared the results by race and family history. In white men with a family history of prostate cancer, 47% had cancer and 30% had Gleason score (GS) ≥ 7 disease. In white men without a family history of prostate cancer, 32% had cancer and 23% had GS ≥ 7 disease. By comparison, in African American men with a family history of prostate cancer, 56% had cancer and 42% had GS ≥ 7 disease. In African American men without a family history, 42% had cancer and 29% had GS ≥ 7 disease. In our study, 144 of 456 (32%) of the group of average-risk men had cancer and 105 of 456 (23%) had GS ≥ 7 cancer. Had the AUA guidelines been followed, these cancers would have been missed or the diagnoses delayed. [Rev Urol. 2017;19(2):106–112 doi: 10.3909/riu0748] © 2017 MedReviews®, LLC

Prostate cancerProstate-specific antigenAUA screening guidelineAverage-risk men

Cynthia L ShamelView Articles
Cynthia MastersView Articles
Dae Kyung KimView Articles
Daisaku HiranoView Articles
Damian HanburyView Articles

Volume 16, Number 1Review Articles

The Physiologic and Anesthetic Considerations in Elderly Patients Undergoing Robotic Renal Surgery

Management Review

Nikhil VasdevTim LaneDamian HanburyAnna Sau Kuk PoonGowrie MohanGregory BousteadJames M Adshead

A number of patients are diagnosed with renal malignancies incidentally worldwide. Once a diagnosis of a renal malignancy is established, after a careful evaluation, patients can be offered a robotic nephrectomy or partial nephrectomy. We present a review of the physiologic and anesthetic considerations in elderly patients who are being considered for robotic renal surgery. [Rev Urol. 2014;16(1):1-9 doi: 10.3909/riu0591] © 2014 MedReviews®, LLC

Robotic partial nephrectomyRobotic radical nephrectomyPhysiologic considerationsAnesthetic considerations

Dan SperlingView Articles

Volume 16, Number 2Review Articles

Focal Laser Ablation for Localized Prostate Cancer: Principles, Clinical Trials, and Our Initial Experience

Treatment Update

Herbert LeporTed LeeNeil MendhirattaDan Sperling

Focal therapy of prostate cancer is an evolving treatment strategy that destroys a predefined region of the prostate gland that harbors clinically significant disease. Although long-term oncologic control has yet to be demonstrated, focal therapy is associated with a marked decrease in treatment-related morbidity. Focal laser ablation is an emerging modality that has several advantages, most notably real-time magnetic resonance imaging (MRI) compatibility. This review presents the principles of laser ablation, the role of multiparametric MRI for delineating the site of significant prostate cancer, a summary of published clinical studies, and our initial experience with 23 patients, criteria for selecting candidates for focal prostate ablation, and speculation regarding future directions. [Rev Urol. 2014;16(2):55-66 doi: 10.3909/riu0615] © 2014 MedReviews® LLC

Prostate cancerFocal therapyTargeted therapyLaser ablation

Dan StoianoviciView Articles
Dan TheodorescuView Articles
Dana JacobyView Articles

Volume 18, Number 3Review Articles

Urology Group Compensation and Ancillary Service Models in an Era of Value-based Care

Health Care Economics

Neal D ShoreDana Jacoby

Changes involving the health care economic landscape have affected physicians’ workflow, productivity, compensation structures, and culture. Ongoing Federal legislation regarding regulatory documentation and imminent payment-changing methodologies have encouraged physician consolidation into larger practices, creating affiliations with hospitals, multidisciplinary medical specialties, and integrated delivery networks. As subspecialization and evolution of care models have accelerated, independent medical groups have broadened ancillary service lines by investing in enterprises that compete with hospital-based (academic and nonacademic) entities, as well as non–physician-owned multispecialty enterprises, for both outpatient and inpatient services. The looming and dramatic shift from volume- to value-based health care compensation will assuredly affect urology group compensation arrangements and productivity formulae. For groups that can implement change rapidly, efficiently, and harmoniously, there will be opportunities to achieve the Triple Aim goals of the Patient Protection and Affordable Care Act, while maintaining a successful medical-financial practice. In summary, implementing new payment algorithms alongside comprehensive care coordination will assist urology groups in addressing the health economic cost and quality challenges that have been historically encountered with fee-for-service systems. Urology group leadership and stakeholders will need to adjust internal processes, methods of care coordination, cultural dependency, and organizational structures in order to create better systems of care and management. In response, ancillary services and patient throughput will need to evolve in order to adequately align quality measurement and reporting systems across provider footprints and patient populations. [Rev Urol. 2016;18(3):143-150 doi: 10.3909/riu0726] © 2016 MedReviews®, LLC

Independent practiceCollaborationValue-based careSpecializationCompensation

Daniel A WollinView Articles

Volume 17, Number 2Case Review

Juxta-adrenal Ancient Schwannoma: A Rare Retroperitoneal Tumor

William C HuangGanesh SivarajanDaniel A WollinPratibha ShuklaJonathan Melamed

Retroperitoneal schwannoma is a rare tumor that is often misdiagnosed as malignancy due to a concerning appearance on cross-sectional imaging. Pathology and immunohistochemistry form the gold standard for diagnosis; as such, local excision is the treatment of choice for this disease. We present two cases of juxta-adrenal ancient schwannoma that were treated with adrenalectomy and discuss the current literature regarding this entity. [Rev Urol. 2015;17(2):97-101 doi: 10.3909/riu0669] © 2015 MedReviews®, LLC

Ancient schwannomaAdrenal tumorAdrenalectomy

Daniel B RukstalisView Articles
Daniel CanterView Articles

Volume 23, Number 2Bladder Cancer

Management of Adverse Events From Checkpoint Inhibitors in Urologic Practice: Where Are We Today?

Caroline BranchDaniel CanterGautam Jayram

Urologic oncology has seen a tremendous impact from the emergence of checkpoint inhibitors in the management of malignant conditions of the urinary tract. These therapies are now in the nonmetastatic setting, and there is ample opportunity to integrate them into urologic practice. The most common barrier to starting a checkpoint inhibitor therapy program is concern about immune-related adverse event management. The evaluation and management of immune-related adverse events can be part of the treatment protocol and centralized to promote safety and success. The key components of implementing an in-office infusion program that includes checkpoint inhibitors are the use of a team-based approach, with a champion physician; appropriate patient education before and during treatment; and timely evaluation and treatment of all adverse events, with subspecialty consultation, if needed.

ImmunotherapyUrologyurinary bladder neoplasms

Daniel G WongView Articles

Volume 21, Number 2Reviews in Urology

Massive Intra-abdominal Germ Cell Tumors: A Case Series and Review of Literature

Nirmish SinglaAditya BagrodiaDaniel G Wong

Intra-abdominal testes are at increased risk of malignant transformation and can manifest as large abdominal masses with a wide variation in presenting symptoms. In the setting of cryptorchid or nonpalpable testes, large abdominal masses are highly suspect for germ cell tumors. Without standard guidelines, management can vary extensively. Surgical management may not be trivial and can entail a major abdominal operation in the context of a multimodal approach. The use of biopsy and serum tumor markers may effectively guide sequence of management based upon expected histology. In advanced cases, neoadjuvant chemotherapy may be pursued, and retroperitoneal lymph node dissection may be accomplished at the time of orchiectomy to minimize morbidity. The development of these massive late stage tumors reaffirms current guidelines on the early correction of cryptorchidism. [Rev Urol. 2019;21(2/3):136–140] © 2019 MedReviews®, LLC

TesticularSeminomaNonseminomatous

Daniel J GeorgeView Articles

Volume 9, Supplement 1Review Articles

Current Standard and Investigational Approaches to the Management of Hormone-Refractory Prostate Cancer

New Directions in the Management of Advanced Prostate Cancer

Andrew J ArmstrongDaniel J GeorgePrateek Mendiratta

Prostate cancer is a common cause of death in men and remains incurable in the metastatic setting. In 2004, 2 landmark trials using docetaxel-based chemotherapy, TAX 327 and SWOG 99-16, showed a survival benefit for the first time in metastatic, hormone-refractory prostate cancer. Current research suggests that several distinct mechanisms of androgen-refractory disease may converge in patients with disease progression on androgen deprivation therapy. These findings have identified several potential targets for therapeutic intervention. Current standard and investigational treatment options for this disease are discussed, including chemotherapy and rapidly evolving therapies in phase II/III trials involving antiangiogenic therapies, signal transduction inhibitors, immunomodulatory agents, and nuclear receptor targets. In light of a growing array of treatment options and an increasingly chronic natural history, this review supports a multidisciplinary care approach to these patients, including medical oncologists, urologists, and radiation oncologists, to optimize survival and quality of life. [Rev Urol. 2007;9(suppl 1):S9-S19]

ChemotherapyZoledronic acidHormone-refractory prostate cancerAntiangiogenic therapySignal transduction inhibitorsImmunomodulatory agents

Daniel J KmetzView Articles

Volume 21, Number 1Case Review

Symptomatic Rosai-Dorfman Disease Presenting as Isolated Bilateral Perinephric Infiltration

Bryant Van LeeuwenDaniel J KmetzDennis Bentley

This case explores a rare initial presentation of Rosai-Dorfman disease isolated to the peri-renal space. Also described as sinus histiocytosis with massive lymphadenopathy, Rosai-Dorfman disease is non-neoplastic and most often presents with massive cervical lymphadenopathy, but the disease can affect any organ system. Not often considered by those in the urology community or found in urology journals, this report reviews a clinical presentation of Rosai-Dorfman disease affecting bilateral kidneys and the fundamental histopathology needed for its diagnosis. [Rev Urol. 2019;21(1):41–44] © 2019 MedReviews®, LLC

Rosai-Dorfman diseaseSinus histiocytosis with massive lymphadenopathy

Daniel J RicchiutiView Articles
Daniel M ArnettView Articles

Volume 15, Number 4Review Articles

The Use of In Vitro Fertilization in the Management of Male Infertility: What the Urologist Needs to Know

Management Review

Randall B MeachamSahar M StephensDaniel M Arnett

Infertility affects approximately 10% to 20% of reproductive-age couples, many of whom may present initially to a urologist. Some couples may be treated medically to increase spontaneous conception rates; however, many will require more aggressive management with in vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI). IVF involves ovarian stimulation, oocyte retrieval, and fertilization outside of the body; ICSI involves injecting one sperm into the oocyte to promote fertilization. Here we provide a brief overview of IVF and ICSI along with a discussion of the risks involved to facilitate the counseling and care of the infertile couple. [Rev Urol. 2013;15(4):154-160 doi: 10.3909/riu0588] © 2014 MedReviews®, LLC

Male infertilityIn vitro fertilizationIntracytoplasmic sperm injection

Daniel P PetrylakView Articles